Coenzyme Q 10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress

BMC Nephrology

Jonathan Himmelfarb⁴  T. Alp Ikizler³  Danny D. Shen⁵  Baohai Shao²  Suhail Ahmad⁴  Mary B. Sundell³  Lori Linke⁴  Baback Roshanravan⁴  Adam J. Claessens⁵  Frederic T. Billings¹  Catherine K. Yeung⁴ 

[1]Division of Critical Care Medicine, Department of Anesthesiology, Vanderbilt University Medical Center, 1211 21st Avenue South, 526 Medical Arts Building, Nashville 37205, TN, USA

[2]Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, WA, USA

[3]Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, S-3223 Medical Center North, Nashville 37232, TN, USA

[4]Department of Medicine, Kidney Research Institute, University of Washington School of Medicine, Seattle 98195, WA, USA

[5]Department of Pharmacy, University of Washington School of Pharmacy, Seattle 98195, WA, USA

关键词: Oxidative stress;    Kidney disease;    Hemodialysis;    Coenzyme Q10;    Clinical study;   

Others  :  1231077
DOI  :  10.1186/s12882-015-0178-2

 received in 2015-04-01, accepted in 2015-10-29,  发布年份 2015

【 摘 要 】

Background

Coenzyme Q ₁₀(CoQ ₁₀ ) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ ₁₀in chronic hemodialysis patients, a population subject to increased oxidative stress.

Methods

We performed a dose escalation study to test the hypothesis that CoQ ₁₀therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F ₂ -isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ ₁₀concentrations were measured to determine dose, concentration and response relationships.

Results

Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ ₁₀levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F ₂ -isoprostane concentrations did not change during the study.

Conclusions

CoQ ₁₀supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ ₁₀supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ ₁₀supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.

Trial Registration

This clinical trial was registered on clinicaltrials.gov [NCT00908297] on May 21, 2009.

【 授权许可】

   
2015 Yeung et al.

【 图 表 】

Fig. 1.

Figure 7.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013. www. usrds.org
• [2]A Data Book: Healthcare Spending and the Medicare Program. 2009.
• [3]Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A et al.. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006; 48(5):752-60.
• [4]Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M et al.. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011; 34(1):12-9.
• [5]Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton). 2012; 17(4):311-21.
• [6]Beyer RE. The participation of coenzyme Q in free radical production and antioxidation. Free Radic Biol Med. 1990; 8(6):545-65.
• [7]Kandar R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed Chromatogr. 2015.
• [8]Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62(5):1524-38.
• [9]Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol. 2008; 19(3):593-9.
• [10]Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE et al.. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005; 38(6):698-710.
• [11]Fessel JP, Hulette C, Powell S, Roberts LJ, Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson’s disease and with dementia with Lewy body disease. J Neurochem. 2003; 85(3):645-50.
• [12]Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts LJ. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A. 2002; 99(26):16713-8.
• [13]Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW et al.. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001; 59(5):1960-6.
• [14]Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM et al.. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002; 58(3):190-7.
• [15]Claessens AJ, Yeung CK, Risler LJ, Phillips BR, Himmelfarb J, Shen DD. Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Ann Clin Biochem. 2015.
• [16]Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007; 2(1):221-6.
• [17]Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A. 2008; 105(34):12224-9.
• [18]Billings FT 4th. Intraoperative normoxia, oxidative damage, and organ injury following cardiac surgery. Shock. 2015;43(S1):24.
• [19]Babb AL, Ahmad S, Bergstrom J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981; 1(1):46-50.
• [20]Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008; 26(4):371-8.
• [21]Singh RB, Kumar A, Niaz MA, Singh RG, Gujrati S, Singh VP et al.. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with End-stage renal failure. J Nutr Environ Med. 2003; 13(1):13-22.
• [22]Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2- isoprostanes and isofurans using gas chromatography–mass spectrometry. Free Radic Biol Med. 2013; 59:36-44.
• [23]Shao B, Heinecke JW. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 2008; 440:33-63.
• [24]von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G. Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res. 1991; 32(9):1465-76.
• [25]Kamimura MA, Draibe SA, Dalboni MA, Cendoroglo M, Avesani CM, Manfredi SR et al.. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant. 2007; 22(3):839-44.
• [26]Baskaran R, Shanmugam S, Nagayya-Sriraman S, Kim JH, Jeong TC, Yong CS et al.. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. Arch Pharm Res. 2008; 31(7):938-44.
• [27]Itagaki S, Ochiai A, Kobayashi M, Sugawara M, Hirano T, Iseki K. Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein. J Agric Food Chem. 2008; 56(16):6923-7.